Skip to main content

Pharmacy news

Find pharmacy-related safety alerts, drug recall and new generic drug announcements and other medication information.

Two pharmacists check their inventory.

Pharmacy news bulletins available on the portal

For a list of pharmacy news bulletins, pharmacists may sign in to the Pharmacist Portal. If you do not have access, you can register for a new account.

The Inflation Reduction Act (IRA) became law on August 16, 2022 and includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government

Additional notifications

Information about the launch of generic Symbicort HFA inhaler

Effective Jan. 1, 2023, generic Symbicort HFA inhaler (budesonide/formoterol inhaler) is not covered or may require step therapy on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Symbicort HFA inhaler will continue to be covered and can be filled for patients.

Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday ─ Friday, 8 a.m. ─ 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Symbicort HFA inhaler FAQs, PDF

Information about the launch of generic Mitigare

Effective Jan. 1, 2023, generic Mitigare (colchicine capsule) is not covered or may require step therapy on Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Mitigare will continue to be covered and can be filled for patients.

Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Mitigare FAQs, PDF

Information about the launch of generic Vascepa

Effective Jan. 1, 2023, generic Vascepa (icosapent) is not covered or may require step therapy on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Vascepa will continue to be covered and can be filled for patients.

Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Vascepa FAQs, PDF

Formulary changes for Revlimid

Lenalidomide, the generic version of Revlimid®, is covered by Humana with a prior authorization and will remain covered in 2023. Effective Jan. 1, 2023, Humana Medicare plans will no longer cover Revlimid. If the generic version is not available at your patient’s pharmacy, please include this information in your coverage exception request. We have notified your patients who had a claim for Revlimid in 2022 about this formulary change.

Prescribers with questions regarding this change may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Information about the launch of generic Flovent HFA

Effective May 28, 2022, generic Flovent HFA (fluticasone propionate) is not covered on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Flovent HFA will continue to be covered and can be filled for patients.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Flovent HFA FAQs, PDF

Information about the launch of generic Breo Ellipta

Effective May 28, 2022, generic Breo Ellipta (fluticasone furoate/vilanterol) is not covered on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans (excluding Value prescription drug plan). Brand-name Breo Ellipta will continue to be covered and can be filled for patients.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Breo Ellipta FAQs, PDF

Information about the launch of generic Restasis

Effective Feb. 12, 2022, generic Restasis (cyclosporine) is not covered or may require prior authorization on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Restasis will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Restasis FAQs , PDF

Information about the launch of generic Combigan

Effective Jan. 22, 2022, generic Combigan (brimonidine-timolol) is not covered on Humana’s commercial, Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Combigan will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Combigan FAQs, PDF

Information about the use of ivermectin and COVID-19

The Centers for Disease Control and Prevention has released a health advisory regarding the rapid increase in ivermectin prescriptions and reports of severe illness associated with the use of products containing ivermectin to prevent and treat COVID-19.

Please see this notice, PDF for more information.

Updates could mean new requirements for Humana members

Beginning Jan. 1, 2022, certain drugs will have new limitations or will require utilization management (e.g., prior authorization [PA] requirements, step therapy [ST] modifications and nonformulary [NF] changes) under the Humana commercial and Medicare formularies for the 2022 plan year.

These changes could mean higher costs or new requirements for Humana members who use these drugs. Humana encourages the use of generic and cost-effective brand medications whenever possible. Depending on the member’s plan, Humana also may make positive and negative midyear changes for both commercial and Medicare formularies.

Information about the launch of generic Durezol

Effective Oct. 1, 2021, generic Durezol (difluprednate) is not covered by Humana’s Medicare Advantage prescription drug and Medicare Part D plans. Brand-name Durezol will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday – Friday, 8 a.m. – 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Generic Durezol FAQs, PDF

Point-of-sale edits for hydroxychloroquine and chloroquine – effective 7/1/20, PDF opens in new window

Information about the launch of authorized generic insulin aspart and insulin aspart mix

Effective Dec. 14, 2019, authorized generics for NovoLog and NovoLog Mix (insulin aspart and insulin aspart mix) came to market. They are currently under evaluation for Humana’s Medicare Advantage prescription drug plans, Medicare Part D plans and commercial plans; brand NovoLog and NovoLog Mix will continue to be covered and can be filled for the patient.

Prescribers with questions regarding this may call 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m., Eastern time. Prescribers in Puerto Rico should call 866-488-5991.

Authorized generic insulin aspart and insulin aspart mix FAQs, PDF

Med-Edit update notification

As of Jan. 1, 2018, Humana Pharmacy Solutions made enhancements to the opioid utilization program point-of-sale edits based on the opioid thresholds below. Please note: Patients with cancer or in hospice will not be flagged for this edit.

Med-Edit Notification, PDF